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Abstract: 
Additive manufacturing processes used to create regenerative bone tissue 
engineered implants are not biocompatible, thereby restricting direct use with stem 
cells and usually require cell seeding post-fabrication. Combined delivery of stem 
cells with the controlled release of osteogenic factors, within a mechanically-strong 
biomaterial combined during manufacturing would replace injectable defect fillers 
(cements) and allow personalized implants to be rapidly prototyped by 3D 
bioprinting.  
Through the use of direct genetic programming via the sustained release of an 
exogenously delivered transcription factor RUNX2 (delivered as recombinant GET-
RUNX2 protein) encapsulated in PLGA microparticles (MPs), we demonstrate that 
human mesenchymal stromal (stem) cells (hMSCs) can be directly fabricated into a 
thermo-sintered 3D bioprintable material and achieve effective osteogenic 
differentiation. Importantly we observed osteogenic programming of gene expression 
by released GET-RUNX2 (8.2-, 3.3- and 3.9-fold increases in OSX, RUNX2 and 
OPN expression, respectively) and calcification (von Kossa staining) in our scaffolds. 
The developed biodegradable PLGA/PEG paste formulation augments high-density 
bone development in a defect model (~2.4-fold increase in high density bone 
volume) and can be used to rapidly prototype clinically-sized hMSC-laden implants 
within minutes using mild, cytocompatible extrusion bioprinting.  
The ability to create mechanically strong cancellous ‘bone-like’ printable implants for 
tissue repair that contain stem cells and controlled-release of programming factors is 
innovative, and will facilitate the development of novel localized delivery approaches 
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to direct cellular behaviour for many regenerative medicine applications including 
those for personalized bone repair. 
 
1. Introduction 
Additive manufacturing of custom, defect-matched implants for regenerative 
medicine has significantly developed over the last decade [1]. For bone tissue 
engineering these approaches employ ceramic and polymeric materials to enable 
bone-like mechanically strong scaffolds to be generated, however the manufacturing 
process may not be bio-compatible (using high-temperatures, UV-light or organic 
solvents) [2]. As such only acellular implants are created and the incorporation of 
stem cells or therapeutic molecules can only occur post-fabrication. This prevents 
uniform seeding, patterning of cells or molecules to produce functionally complex 
tissues and long-term delivery is inhibited; thus bio-inductive strategies are often not 
effective or have less controlled activity [1]. Development of production processes 
which can be used intraoperatively; with cells and biomolecules directly included in 
the process is therefore vital for their use clinically. 
Successful regenerative medicine strategies often rely on exquisite control of the 
biological microenvironment and supplementation of extrinsic therapeutic molecules 
to orchestrate cellular behaviour. Cellular processes like migration, proliferation, 
adhesion and differentiation occur in response to chemical cues present within the 
microenvironment such as interaction with extracellular matrix (ECM) and stimulation 
with morphogens or growth factors (GFs) [3, 4]. These macromolecules trigger 
intracellular signal transduction pathways, with complex cross-talk between 
signalling cascades and eventual programming of cell behaviour through 
transcription factors (TFs) [4-6]. Directed cell differentiation can be achieved through 
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the use of chemical induction or exogenous GFs or hormones, which might have 
non-specific pleiotropic effects. Therefore, there is a need for more efficient and 
targeted molecules that can be used in regenerative medicine. TFs can provide 
specific regulatory effect, which is considered ideal for cell fate; however, these TFs 
are difficult to deliver intracellularly.  
Glycosaminoglycan-binding Enhanced Transduction (GET) peptides [7-14] are 
delivery peptides that enhance transduction and endosomal escape of cargoes in 
cells. GET peptides contain Heparan Sulphate (HS) binding motifs that enhance 
binding to cell surface glycosaminoglycans (GAGs) which concentrate the cargo on 
cell membranes, combined with cell penetrating peptide (CPP) and endosomal 
escaping peptide elements to mediate uptake and escape, respectively. We have 
previously published the enhanced delivery characteristics and versatility of GET 
peptides, used as synthesized L-amino acid peptides or recombinant protein fusions 
to deliver recombinant proteins [9] [15], nucleic acids (pDNA, mRNA, siRNA) [7, 11, 
12] and magnetic nanoparticles [14]. 
Our recent work has shown that recombinant TFs can be expressed, purified and 
delivered efficiently to control cell behaviour for various applications [7]. This system 
can be utilized to regenerate tissues if these molecules are supplied at functional 
dose, duration and location. Osteogenic TF, RUNX2 (also called Core-binding factor 
alpha, CBFa1) is essential for osteoblast commitment, differentiation, matrix 
production, and mineralization during bone formation [16]. RUNX2 regulates 
downstream genes that determine the osteoblast phenotype and controls the 
expression of osteogenic marker genes such as ALP, OP, OSX, COL1A1 (type-I 
collagen), BSP, and OCN [17-20] in response to physiological signals [21].  
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We previously showed that GET-RUNX2 can be used to direct human Mesenchymal 
Stromal Cells (hMSCs) towards osteogenesis, removing the need to use pleiotropic 
compounds (such as dexamethasone), or GFs (such as BMP2) which may trigger 
unwanted off-target cellular responses. However, this TF needs to be supplied at a 
specific dose over a period of time for osteogenic induction [9]. 
Importantly, we have also shown the utility of GET peptides in regenerative medicine 
by delivering TFs RUNX2 and MYOD for osteogenesis and zonal myogenesis in 
three‐dimensional gradients [9, 22], respectively. Moreover, GET peptides have 
been used to enhance the delivery and transfection of nucleic acids for lung gene 
therapy and bone regeneration in vivo [11, 12]. The latter delivering GF genes to 
enhance the repair of a critical size calvarial bone defect in rats [12].  
Controlled and localized release of therapeutic molecules is one of the main factors 
that affect tissue regeneration within a scaffold [23]. The combination of biomaterials 
(scaffolds component), cells and therapeutic molecules can be used for localized 
and targeted regeneration therapies [24]. Poly-(DL-lactic acid-co-glycolic acid) 
(PLGA), which has been extensively studied as a degradable implant material [25], 
was used as a scaffold to study bone regeneration given its mechanical properties 
and enhanced mineralized tissue formation from its osteoconductive properties [26]. 
It has been shown that mixing PLGA with a plasticizer (such as Poly(ethylene 
glycol); PEG) will produce temperature-sensitive particles with a reduced glass 
transition temperature (Tg) of 37°C [27]. When these particles are mixed with an 
aqueous carrier solution at room temperature an extrudable paste is formed that can 
be moulded into any size or shape. Incubation of these pastes at 37°C, surrounded 
by aqueous fluid leads to thermoresponsive liquid sintering and the formation of 
porous solid constructs [22–27]. These constructs can be engineered with 
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mechanical properties which are comparable to those of human cancellous bone 
[22–25, 28–31]. Previous studies utilizing this material have shown that proteins 
[24, 26, 27][28] and cells [22, 24][28] can tolerate the mixing and extrusion 
processes while maintaining activity and viability respectively. Encapsulated proteins 
can be delivered over several weeks [27] and the microporosity inherent to these 
constructs, may also have beneficial effects on tissue ingrowth and angiogenesis in 
vivo.  
Our recent study demonstrated that GET-tagged reporter peptides (mRFP, red 
fluorescent protein) could be efficiently encapsulated and its release controlled in 
PLGA microparticles (MPs) [15]. Moreover, this delivery system could provide 
sustained release of GET peptides for at least 7 days, without loss of transduction 
activity. In the current study, we hypothesized that these MPs could be employed to 
provide a sustained release system for TFs needed to promote osteogenesis of 
hMSCs. Herein, we have utilized biomaterials, cells and a therapeutic recombinant 
molecule to demonstrate that a combined system can be rapidly fabricated into 
mechanically strong osteogenic scaffolds or implants. GET-RUNX2 (RUNX2) loaded 
MPs, mixed with modified PLGA/PEG paste formulations was developed to provide a 
controlled release delivery of an osteogenic TF, a compatible microenvironment for 
the stem cells to generate new bone, and a system to deliver a mechanically strong 
implantable material, both in vitro and in vivo.  
In this study, we aimed to demonstrate the efficient encapsulation, and release of 
active GET-RUNX2 protein from PLGA MPs which could be combined in a 
mechanically strong, 3D printable material. An innovative combined approach could 
have significant impact on clinical application of regenerative medicine in bone 
repair. Importantly, incorporation of viable hMSCs and a cell-fate programming 
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system into a bioprinting process to produce osteogenic living implants could be 
demonstrated. The combination of this complete tractable system is the novelty and 
significance of our system. 
 
2. Materials and Methods 
2.1 Protein synthesis and FITC tagging 
CPP (eight arginine, termed 8R) and heparin binding domain (HBD, termed P21), 
which compose the Glycosaminoglycan – binding enhanced transduction (GET) 
system were used to tag the RUNX2 ORF to allow production of P21-RUNX2-8R 
protein [9]. cDNA constructs containing 8R, RUNX2 and P21 sequences were 
synthesized de novo (Eurofins MWG Operon, Ebersberg, Germany) and cloned into 
pGEX6‐P1 expression vector (Novagen Watford, U.K.) [9]. Recombinant protein was 
expressed and purified as previously described in [29]. For protein tracking, P21-
RUNX2-8R was tagged with FITC using NHS-Fluorescein as per manufacturer’s 
instructions (Thermo Scientific) at 1:50 protein: label molar ratio and purified/buffer 
exchanged to PBS using Bio-Spin P-6 spin columns (Bio-Rad, Watford, UK). 
 
2.2 PLGA Microparticle fabrication 
Poly (D,L-lactide-co-glycolide, (PLGA) LA:GA ratio: 50:50; Mw 52 kDa, Evonik 
Industries, USA) MPs were formed using solid-in-oil-in-water (S/O/W) emulsion as 
previously described [15, 30]. Briefly, 1 mg of P21-RUNX2-8R, was mixed with 0.5 
mg PEG 6000 (Sigma-Aldrich, UK) and 0.25mg L-Histidine (Sigma-Aldrich, UK) and 
freeze dried overnight. Blank MPs were prepared by freeze drying 0.5 mg PEG 6000 
only. PLGA was dissolved in dichloromethane (DCM, Fisher, UK) (200 mg of PLGA 
was dissolved in 1.5 ml DCM) and added to the freeze dried powder. The theoretical 
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GET-RUNX2 loading was 1mg in 200mg PLGA (0.5%) The solution was then mixed 
by vortexing. Two hundred microliters of phosphate buffered saline (PBS, Gibco, UK) 
was added to the solution and vortexed to produce a homogenous emulsion. Four 
millilitres of 0.25% (w/v) methylcellulose (Sigma-Aldrich, UK) solution was then 
added to the mixture and vortexed again. The resultant emulsion was then poured 
into 400 ml of distilled water; and the resultant (S/O/W) emulsion was left stirring for 
3 h to allow DCM evaporation. The hardened MPs were then collected by 
centrifugation and washed three times with distilled water. The obtained MPs were 
then freeze dried (Edwards Modulyo D IMA Edwards, UK) for 24h. 
 
2.3 Extrusion Bioprinting 
A RegenHU 3D Discovery system (Switzerland) was used for 3D printing with Huber 
Pilot ONE temperature controller (Switzerland). PLGA/PEG particles (≤50 μm) were 
mixed by spatula with different carriers, cells and microparticles at 4°C before being 
transferred into a sterile syringe. Mixing was performed until a homogenous colour 
(of the phenol-red cell culture media) was achieved as previously achieved [31]. 
Syringes were placed into the printer mount and allowed to equilibrate with the 
printing temperature (25°C). During printing, the pressure was manually adjusted (1-
3 bar) to ensure adequate flow of material through the 20 gauge (0.61mm) tapered 
syringe tip (Adhesive dispensing Ltd. UK). The print speed varied between 20 and 60 
mm/s. BioCAD software (RegenHU) was used to design the lattice structure to be 
printed. Dissection microscope Nikon SMZ1500 was used to image the printed 
structures. For 3D printing of the L5 vertebra, SLS files were downloaded from: 
http://www.thingiverse.com/thing:781206. For L5 vertebrate; PLGA/PEG with 
Jo
urn
al
Pr
e-p
ro
f
Journal Pre-proof
 9 
 
Pluronic F-127 (PF-127) 18% (with 1% Tri-acetin) 1:1.5 ratio was mixed and loaded 
to the printer, the printing temperature was 25°C. 
 
2.4 Cell seeding pre-fabrication 
Cells were mixed with the carrier (18% PF-127 with 1% Tri-acetin) with final density 
of 1x107/ml and mixed with PLGA/PEG particles in 1:1.5 (PLGA/PEG:carrier, w/v) 
ratio at 4°C as described previously [31]. The resultant mixture was then loaded to 
the mould or printing syringe and heated to 25°C. The mixture was then printed, and 
sintered at 37°C for 30 minutes. The sintered scaffolds were then washed in cold 
PBS for 45 minutes and then cultured in cell culture media. 
 
2.5 Cell seeding post-fabrication  
To ensure sterility, the scaffolds were treated with 1% antibiotic and antimycotic 
solution for 20 minutes at 370 C and washed extensively with sterile PBS as 
previously described [15, 32]. Fifty thousand cells in 20µL suspension was pipetted 
onto each sintered scaffold. The scaffolds were incubated for 1 hour at 37ºC, to 
allow attachment, prior to addition of 1ml media to each well.  
 
2.6 Osteogenesis assay 
DMEM: F12 media (Life technologies, Paisley, UK) supplemented with 10% (v/v) 
fetal bovine serum, 2mM L-glutamine, 100 units/ml penicillin and 100 μg/ml 
streptomycin (Sigma) was used as the basal media for osteogenic media. Fifty 
thousand cells per scaffold (containing blank MPs or P21-RUNX2-8R loaded MPs) 
were seeded and cultured for 4 weeks depending on the experiment with appropriate 
media. 50 μg/ml L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate 
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(Sigma) and 10 mM β glycerophosphate disodium salt pentahydrate (Acros 
Organics) were added to the basal media for osteo-permissive medium (OP). To 
make osteo-inductive media (OI), 100 nM Dexamethasone (Sigma) was added to the 
osteo-permissive (OP) medium. Cells were cultured for 3-4 weeks for complete 
osteogenesis. Medium was changed every other day. 
 
2.7 Cell viability assay 
PrestoBlue® cell viability assays (Invitrogen Life Sciences, UK) were performed on 
day 3, 6 and 9 post-seeding on three scaffolds per time point. Each scaffold was 
submerged in 900µl of media and 100µl of PrestoBlue was added to each well and 
mixed. The scaffolds were then incubated at 37ºC for 2 hours. Three 100µl media 
samples were taken from each well and were read on Tecan plate reader with the 
excitation wavelength set to 560 nm and the emission wavelength set at 590 nm. 
Blank sample readings were subtracted and results were compared with 
corresponding standard curve of known cell numbers to calculate the number of cells 
per scaffold. 
 
2.8 In vivo bone defect assay and µCT 
hMSC populations were selected by magnetic separation (STRO-1+) from adherent 
mononuclear cell fractions from human bone marrow obtained during routine 
knee/hip replacement surgeries with full ethical approval and patient consent. Briefly, 
bone marrow aspirate was thinned with basal media (DMEM supplemented with 10% 
(v/v) FBS, 1% (v/v) sodium pyruvate, 1% (v/v) non-essential amino acids, 1% (v/v) 
penicillin-streptomycin, 1% (v/v) l-glutamine, and layered onto Lymphoprep density 
gradient media (Stem Cell Technologies). Following centrifugation at 800x g for 40 
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min, the intermediate interface of mononuclear cells was removed and washed three 
times with media. These cells were then selected for the marker STRO-1 using an 
in-house STRO-1 antibody (original hybridoma courtesy of Dr Beresford, University 
of Bath, UK) using a MACS kit from Miltenyi Biotech as previously detailed [33]. Only 
adherent STRO-1+ cells were cultured. Cells from two patients were used in two 
separate experiments. Scaffold containing P21-mRFP-8R or P21-RUNX2-8R MPs 
were cut into approximately 1 mm3 sized pieces and 1-3x104 STRO-1+ hMSCs were 
added to each scaffold. Cells were incubated on the scaffold at 37 °C, 5 % CO2 for 
3-4 days. All in vivo studies were undertaken following approval from the local 
Animal Welfare and Ethics Review Board (AWERB) University of Southampton and 
carried out in accordance with the guidelines and regulations stipulated in the 
Animals (Scientific Procedures) Act, UK 1986 under the approved Home Office 
Project license (PPL 96B16FBD). All mice were raised within the University of 
Southampton Biomedical Research Facility and were housed in appropriate 
environments in rooms maintained at 22 ± 2 °C with a 12 h light: 12 h dark cycle. 
Eight week old male athymic nude BALB/c mice were used for the study with 4-6 
animals per group per patient. A 1 mm drill-hole defect was made in the right distal 
femur, and then a single 1 mm3 scaffold piece with hMSCs was added to the hole. 
After surgery and at 2 weekly intervals, mice were anaesthetized using isoflurane 
inhalation. Femora were scanned using a Skyscan 1176 in vivo micro-CT scanner 
(Bruker microCT, Kontich, Belgium). All scans were taken at 65 kV, 385 µA with 1 
mm aluminium filter, and 0.7 ° rotation step. Individual 2D cross-sectional images 
were reconstructed using Bruker NRecon software version 1.6.10.2. Voxel resolution 
was 35 µm. All reconstructed bones were set to the same orientation with the 
transverse plane perpendicular to the long axis of the bone using Bruker Dataviewer 
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software. For each animal, the scan at the time of surgery (week 0) was used as a 
reference, and subsequent scans were aligned to this scan using 3D Registration in 
Dataviewer. A 1mm diameter volume of interest centred on the defect hole at week 
0, was used on all subsequent scans to determine bone volume and density at the 
defect site. The depth of the defect is the thickness of the cortical bone (approx. 
250µm). The images are semi-transparent and represent the bone density for the 
entire 3D reconstruction. High density bone was defined based on the intensity of 
signal measured by µCT as we have previously published [34] (lowest density bone 
set at 0.25 g/cm3).   
 
2.9 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism (version 7). For ALP 
assays the statistical significance was determined using one-way ANOVA with Holm-
Sidak post hoc test for ALP study. For gene expression analyses. proliferation and 
mechanical testing data was analysed by two-way ANOVA and Tukey’s test 
assuming confidence levels of 95% (p < 0.05). For mechanical testing the 
homogeneity of variances across experimental groups was determined by Levene’s 
test. Appropriate post hoc procedures were used after one way ANOVA for pairwise 
comparison of experimental groups. In cases of equal variance Tukey’s procedure 
was applied, whilst the Games-Howell procedure was used for cases of unequal 
variance. For the in vivo study, significance was determined using independent 
sample t-test in SPSS version 25 (IBM, Woking, UK). Results were considered 
significant at p < 0.05, mean values are given plus or minus the standard deviation 
(SD) or Standard error or the mean (SE). 
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3. Results 
3.1 Efficient encapsulation and controlled release of GET-RUNX2 
PLGA MPs were fabricated using an optimized S/O/W double emulsion process and 
encapsulated GET-tagged RUNX2 protein (P21-RUNX2-8R, termed GET-RUNX2). 
PBS was added to the formulation to increase porosity thereby accelerating the 
protein release [15]. PBS acts as a porogen, which is expected to increase MP 
porosity and generate channels within and on the MP surface. Porous MPs were 
needed to accelerate the GET-RUNX2 release as previously shown [15]. MPs 
prepared using the S/O/W methodology showed spherical structure with smooth and 
porous surface due to the addition of PBS (Fig. 1A&B). Porosity of the fabricated 
PLGA MPs was assessed visually using SEM images and these were similar to 
those in our previous work [15]. The mean diameter of the MPs was 36.5 ± 7.2 µm, 
with average loading efficiency of 58.4 ± 7.0% (generating 2.9 ± 0.2µg per mg of 
PLGA MPs) (Fig. 1C & S1). P21-RUNX2-8R MP dose was optimized to obtain 
release quantities matching or greater than the dose needed (60µg GET-RUNX2 
during the first week) to initiate osteogenic differentiation of hMSCs [9]. The release 
profile showed comparable GET-RUNX2 quantities (i.e. 30µg in the burst release 
phase and a further 30µg over 5 days) (Fig. 1D&E). Moreover, this represented more 
than 90% of the protein loaded in MPs, which confirmed that minimal protein is 
released after the first week. This was important as RUNX2 activity is needed 
predominantly during the early stages of osteogenesis, and overexpression or 
prolonged activity of RUNX2 during later stages delays matrix mineralization [35]. 
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3.2 PLGA released GET-RUNX2 retains intracellular transcriptional activity 
As GET-RUNX2 can be encapsulated and released in osteogenic-inductive 
quantities from fabricated PLGA MPs, it was crucial to demonstrate that it also 
retained its biological activity (both transducing into cells via the GET peptides and 
retained transcriptional activity). We previously demonstrated that PLGA MPs benefit 
from the inclusion of L-Histidine during fabrication to maintain the macropinocytotic-
activity of GET peptides [15]. L-Histidine is needed to maintain complete activity of 
GET peptides upon increased acidity in the microenvironment within the PLGA MPs 
[15]. The transduction activity of GET-RUNX2 was confirmed by comparing released 
protein to non-encapsulated controls. To facilitate visualization, we labelled GET-
RUNX2 with FITC (NHS-fluorescein). Released GET-RUNX2-FITC was collected 
over the 7 day time course and was incubated with plated hMSCs to assess 
internalization (Fig. 2A), transduction (Fig. 2B&C) and transcriptional activity 
(Fig.2D). Importantly, we compared the released samples to non-encapsulated 
‘fresh’ controls diluted to the same final concentration (i.e. the released protein was 
quantified and compared against fresh protein sample of the same concentration). 
Incubated cells were then evaluated for transduction by fluorescence microscopy 
and flow cytometry analyses (Fig. 2A&B). Fluorescent microscopy showed significant 
GET protein internalization for the collected samples released from PLGA MPs (Fig. 
2A). Flow cytometry results showed high transduction activity with relative 
transduction activity not statistically different (~70% of ‘fresh’ GET-RUNX2 levels) for 
all the studied samples (Fig. 2B&C). Therefore it was clear that the released protein 
retained their transduction activity throughout at least a 7 day release period.  
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In order to study the transcriptional activity of the released GET-RUNX2, the 
immediate transcriptional activation of a RUNX2-responsive luciferase reporter 
containing the transcriptional responsive sequence from the OSTEOCALCIN (OCN) 
promoter (mOG2-Luc) was tested (Fig.2D), as used previously  [9]. The activity of 
the released GET-RUNX2 samples was compared with non-encapsulated ‘fresh’ 
GET-RUNX2. Cells were exposed to the released GET-RUNX2 before and after 
reporter transfection which generates the most pronounced transcriptional activity as 
previously shown [9]. We observed that the released GET-RUNX2 (collected at day 
1 and 2) induced mOG2-Luc reporter expression to a magnitude comparable to the 
‘fresh’ GET-RUNX2 (i.e. 1.57 (±0.51) fold verses 2.21 (±0.21) fold respectively). 
Transcriptional activity enhancement was not significant post-day 2 due to the 
smaller amounts of GET-RUNX2 released. Although this assay is not highly 
responsive, transcriptional enhancement was shown significant for immediate activity 
above control untreated levels. These findings clearly indicate that the released 
GET-RUNX2 retained its transduction and transcriptional activity upon releasing from 
PLGA MPs. 
 
3.3 PLGA/PEG scaffolds support hMSC attachment and proliferation 
In order to generate a delivery vehicle for cells and MPs, and capacity for localized 
delivery of GET-RUNX2, scaffolds were prepared aiming to incorporate the 
fabricated MPs with seeded cells on top or within them. The goal was to finally 
incorporate the full system with hMSCs and GET-RUNX2 MPs into a 3D bioprintable 
formulation. 
Our previously developed temperature sensitive scaffold (composed of PLGA/PEG) 
was used [15]. This system allows incorporation of PLGA MPs with the PLGA/PEG 
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scaffold particles that will sinter to form a hard porous scaffold at 37°C, whereas, at 
room temperature the mixture remains as a paste. PLGA/PEG temperature sensitive 
particles were prepared as previously detailed [15] (Fig. 3A). GET-RUNX2 loaded 
MPs were mixed with PBS and the PLGA/PEG material before sintering, the material 
was then loaded into PTFE moulds creating cylindrical scaffolds (3mm depth x 6mm 
diameter) and sintered for 2 hours at 37°C. Blank MPs were used for non-loaded 
scaffold controls. Initially, hMSCs were seeded on these sintered scaffolds and 
cultured for further studies. PrestoBlue assay was performed on days 3, 6 & 9 to 
confirm cell metabolism and therefore viability on scaffolds. The results 
demonstrated that the scaffold is conducive for cell proliferation (i.e. cell number 
increased from around 40,000 at day 3 to around 65,000 at day 9) (Fig. 3B). SEM 
images showed a different surface morphology for cell-seeded scaffolds (compared 
to non-seeded scaffold) with cells covering the scaffolds with no vacant pores on the 
surface (Fig. 3C-H). This was similar to previous analyses of cell attachment and 
growth on PLGA/PEG scaffolds [27]. 
 
3.4 hMSCs differentiate in response to GET-RUNX2 released from PLGA MPs 
For hMSC osteogenic differentiation in vitro, ascorbic acid and β-glycerophosphate 
are essential for final stages of bone nodule formation by promoting collagen matrix 
production and providing inorganic phosphate for mineralization, respectively. In 
order to test the effect of GET-RUNX2 on bone differentiation, media containing 
these additives (termed ‘osteo-permissive’, OP) was used during differentiation 
studies. hMSCs were seeded on scaffolds containing either GET-RUNX2-loaded 
MPs or blank MPs. Osteo-inductive media (OI) containing 100nM Dexamethasone 
(along with 50 µg/ml ascorbic acid and 10 mM β-glycerophosphate) was used as a 
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positive control on scaffolds containing blank MPs. A full assessment of osteogenic 
differentiation was carried out at different stages using Alkaline phosphatase (ALP) 
quantification and quantitative gene expression analyses (Q RT-PCR) at week 1, 
OCN staining and Q RT-PCR at week 2, and von Kossa staining at week 3. 
ALP assays were performed on three types of scaffolds; blank scaffolds in OP 
media, blank scaffolds in OI media and GET-RUNX2 (RUNX) loaded scaffolds in OP 
media. ALP levels, as measured by absorbance at 405 nm, were comparable 
between GET-RUNX2 loaded scaffolds and the scaffolds in OI media and 
significantly higher than the blank scaffolds cultured in OP media (Fig. 4A). 
OSTEOCALCIN (OCN) is a bone-specific protein synthesized by osteoblasts and its 
expression confirms full osteogenic commitment before progression towards bone 
nodule formation [36-38]. OCN staining was therefore conducted at day 14 post-
fabrication (Fig. 4B). Expression of OCN was visually comparable to scaffolds 
cultured in OI media and those containing GET-RUNX2 loaded MPs. On the other 
hand, there was minimal OCN expression observed in blank scaffolds seeded in OP 
media (Fig. 4B). Mineralization was assessed using von Kossa staining at day 21 
(Fig. 4C). Bone nodules (black material) were visible in scaffolds seeded in OI media 
and scaffolds containing P21-RUNX2-8R loaded MPs. All tested scaffolds showed 
the white composite PLGA scaffold, which was less evident in more differentiated 
conditions (with GET-RUNX2 MPs or with OI) due to being coated with black von 
Kossa stained mineral deposits.  
Finally, we studied the molecular effects of GET-RUNX2 loaded MPs on early and 
late osteogenic gene induction in hMSCs by Q RT-PCR (Fig. 5). Significant 
activation of osteogenic genes could be observed in GET-RUNX2 loaded cells in 
both week 1 and 2. As expected, GET-RUNX2 loaded MPs released active P21-
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RUNX2-8R which induced endogenous RUNX2 expression in hMSCs after week 1 
(Fig. 5A). OSTERIX (OSX), one of the prime target genes for RUNX2 is significantly 
activated (8.2 fold over non-induced control; p<0.05) in week 1 of GET-RUNX2 
loaded hMSCs (Fig. 5A). Expression of these two genes in GET-RUNX2-loaded MP 
cells was similar to cells cultured on scaffolds in OI medium (positive control). 
OSTEOPONTIN (OPN), a bone matrix protein [39] however was lower in GET-
RUNX2-loaded MP cells in comparison to positive control cells at week 2 (Fig. 5B). 
This may be due to the continuing release of RUNX2 which would be hypothesized 
to delay terminal differentiation of the hMSCs in comparison to the OI positive 
control. 
 
3.5 hMSCs colonize the surface of PLGA/PEG scaffolds 
We conducted SEM evaluation of scaffolds at day 21. Scaffolds without cells 
(incubated in media for 21 days) were tested to evaluate polymer degradation. The 
cell-seeded scaffolds showed less porosity as the cells completely covered the 
surface as we have observed previously [27]. Cells were seen to only grow 
significantly on the surface (as shown in the scaffolds cut in half, Fig. S2C,F,I,L) 
which can be attributed to poor migration into scaffold pores as well as the lower 
porosity of the prepared scaffolds. The media used (OP or OI) did not have an overt 
impact on cell morphology, as in both cases the cells covered the scaffolds with no 
noticeable difference (Fig. S2).  The microstructure evaluation of scaffolds (using 
micro (µ)CT) showed comparable results between all scaffolds (Fig. S3). The cell 
distribution was mainly on the surface of the scaffolds, with little cells within the 
scaffold structure, as seen in SEM images of scaffold cross section (Fig. S2). This 
was similar to previous extensive studies with cells on this material [27]. Specifically 
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scaffolds that had the highest osteogenic differentiation; those with GET-RUNX2 
MPs (Fig. S3C) and those cultured in OI media (Fig. S3D) had lower internal 
numbers of hMSCs (density of blue signal). This may be expected as differentiating 
hMSCs will have lower proliferation rates. 
 
3.6 PLGA/PEG particles can be 3D printed by addition of Pluronic F127 
Pluronic(P) F127 is a temperature-sensitive FDA approved polaxmer [40], formulated 
as a triblock copolymer of poly (ethyleneoxide)/poly (propyleneoxide)/poly 
(ethyleneoxide) [40-42]. PF127 has thermo-reversible gelation properties and has 
been widely used as cell carrier and for various 3D printing applications [40-43]. At 
certain concentrations, aqueous PF127 solutions gel at physiological temperatures 
[40]. In order to develop a printable formulation of our system, the material would 
have to possess a certain level of viscosity [44, 45] that allows continuous flow of the 
material through an extrusion printing head/needle. Previously this material has been 
successfully combined with several carriers to allow 3D printing, and sintering in the 
presence of proteins and cells [28]. In order to achieve the needed viscosity, we 
tested the use of PF127, pre-mixed before sintering with the PLGA/PEG particles. 
PLGA/PEG successfully sintered in our groups previous studies [31]. No MPs were 
included at this stage to allow the optimization of an extrudable formulation and 
printing process, once the parameters had been optimized, the MPs were included 
into the system. Viscosity for various concentrations of PF127 at different 
temperatures was studied. It was concluded that suitable PF127 concentration for 
printing should be between 15 – 20 % (w/v). The temperature was fixed at 25°C 
using a heated print head with PF-127 being a gel at this temperature and with sheer 
thinning suitable for printing (Fig. S4 shows concentrations and ratios for printing and 
Jo
urn
al 
Pr
e-p
roo
f
Journal Pre-proof
 20 
 
example tests). From our analyses it was clear that the most suitable printing 
concentration was 18% (w/v) PF127 added in 1:1.5 ratio (PLGA/PEG 
particles:PF127) which allowed extrusion and PLGA/PEG sintering. There was no 
appreciable change in mechanical properties with handling of the sintered 
PLGA/PEG scaffold with addition of PF127 at these concentrations. PF127-
containing scaffolds displayed compressive strength (0.88±0.06 MPa) (Fig. S5A) and 
elastic (Young’s) modulus (7.87±0.01 MPa) (Fig. S5B), similar to previously 
published (0.92±0.05 and 8.76±0.05) with four hours sintering [31]. A further 
modification was developed to accelerate the sintering of printed scaffolds containing 
PF127. Tri-acetin (1%) was added to the PF127 solution; Tri-acetin is a plasticizer 
[46, 47] and reduces the time needed to stabilize scaffolds before media is added 
(from 2h down to 30mins to remain intact). Addition of Tri-acetin to PF127-containing 
scaffolds accelerated compressive strength (0.56±0.09 verses 0.29±0.03 MPa with 
and without, respectively at 30mins) (Fig. S6A) and elastic (Young’s) modulus 
(1.04±0.04 verses 2.76±0.03 MPa with and without, respectively at 30mins) (Fig. 
S6B) [31]. Importantly, although these values are lower than those obtained in other 
bone tissue engineering studies with harsher fabrication they are nonetheless within 
the normal ranges for cancellous bone and mechanically strong [22–25, 28–31]. 
 
3.7 Scaffold integrity is retained with Pluronic F127 which can be removed 
rapidly with low temperature washing 
At a temperature of 37°C, PF127 forms an unstable gel which persists even when 
immersed in culture media for extended periods [40] and can affect cell viability [41]. 
Therefore, we hypothesized that PF127 would be best removed, and possibly this 
could be achievable by diluting it away at lower temperatures.  
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Accordingly, scaffolds were washed in PBS at 4°C for up to 45 minutes after 
sintering and placed at 37°C for 30 minutes. As a control to evaluate the washing 
efficiency, scaffolds were also washed in PBS at 37°C. It was thought that if the 
washing process was not efficient at 4°C, the remaining PF127 would gel at 37°C 
and the scaffolds would swell. The scaffolds washed at 4°C for over 10mins in cold 
PBS showed smooth structure with no swelling (Fig. S7), on the other hand, 
scaffolds washed at 37°C showed swollen structure with PF127 adsorbed on the 
surface and the gel retained (Fig. S7). Mechanical testing of PF127-containing 
scaffolds (with Tri-acetin) with and without cold PBS washes showed minimal effect 
on both compressive (1.47±0.08 verses 1.58±0.07 MPa with and without, 
respectively at 4 hours) (Fig. S6A) and elastic (Young’s) modulus (10.85±0.26 
verses 11.23±0.12 MPa with and without, respectively at 4 hours) of scaffolds (Fig. 
S6B). Mechanical strength within the range of cancellous bone [22–25, 28–31] was 
therefore retained with PF127 removal. 
 
3.8  hMSCs proliferate on scaffolds after removal of Pluronic F127 
After optimizing the formulation for printing with the addition and removal of PF127, it 
was important to determine the cell density optimal for printing, viability and 
differentiation, and to study the effect of the whole process on cell viability and 
proliferation. Accordingly, various cell densities were studied and cell proliferation 
was tested. The scaffolds were prepared by mixing immortalized hMSCs (ihMSCs) 
with PLGA/PEG particles (using 18% PF127 with 1% Tri-acetin at 1:1.5 ratio 
(PLGA/PEG:carrier) formulation). The tested cell densities (0, 0.05, 0.1, 0.25, 0.5 
and 1x106 per scaffold) were mixed, and the paste was loaded into PTFE moulds 
and sintered at 37°C. The scaffolds were then washed in PBS at 4°C for 45 minutes. 
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Scaffold disintegration was evaluated before and after washing by microscopy (Fig. 
S8A). The results showed that intact sintered scaffolds (scaffolds were sintered for 
30 minutes at 37°C) remained intact after washing in PBS at 4°C (Fig. S8A), 
indicating that the sintering time was enough for the scaffolds to maintain the 
structure and that PF127 removal did not significantly affect the scaffold structure nor 
integrity. This mirrored the mechanical testing previously demonstrating strong 
scaffold generation (Fig. S6 & S7) [31]. Scaffolds were cultured in growth media at 
37°C, with PrestoBlue cell metabolism assays performed to assess cell survival and 
proliferation (Fig. S8B). Increased initial cell concentrations resulted in enhanced cell 
retention in the scaffolds during washing and more robust attachment and 
proliferation over the 10 day assessment (Fig. S8B). Any cell number >0.1x106 
cells/scaffold showed effective proliferation, with 1x106 cells likely to have saturated 
the scaffolds at day 5-7 (with a plateau in metabolic activity). This demonstrated that 
addition of PF127 and Tri-actin, sintering, washing and subsequent culture was 
compatible with ihMSC viability and proliferation. 
 
3.9 Successful cytocompatible bioprinting of hMSC-laden PLGA/PEG scaffolds 
The final aim of our studies was to fully confirm that the developed system was a 3D 
bioprintable scaffold able to be co-printed with viable stem cells and provide an 
osteopermissive hard yet porous structure for bone regeneration applications. As a 
full demonstration, ihMSCs were added to carrier (18% PF127 with 1% Tri-acetin) 
with final density of 1x107/ml (equivalent to 0.5x106/moulded scaffold) and mixed 
with PLGA/PEG particles in 1:1.5 ratio at 4°C. The mixture was then loaded to the 
printing syringe and heated to 25°C. The mixture was then printed, and sintered at 
37°C for 30 mins. The sintered scaffolds were then washed in cold PBS for 45 
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minutes and then cultured in media for 7 days. In order to test cell viability and 
proliferation, we again conducted PrestoBlue cell assays on days 1, 3, 5 and 7 post-
fabrication (Fig. 6B). In addition, toluidine blue staining was carried out on day 7 to 
visualize cells directly on scaffolds (Fig. 6C&D). Cells demonstrated proliferation with 
increased culture time relative to day 1 (Fig. 6B). Toluidine blue staining showed 
distribution of the cells along the printed scaffold strand (Fig. 6C), as well as within 
the strand, shown by breaking and imaging a strand cross-section (Fig. 6D). Cells 
appeared more densely populated within scaffolds due to them filling large pores 
inside the material. To fully demonstrate the utility of our system we 3D bioprinted a 
human-scale implant containing hMSCs (Fig. 7). We modified a STL scan file of a 
male adult L5 vertebra (Fig. 7A&B); dividing the structure into two halves to allow 
compatibility with our bioprinting system. We demonstrated the printing of the entire 
clinically sized implant in <8 mins (4 mins per half implant) (Fig. 7C, Video S1), which 
also incorporated complexity such as overhangs and was several cm3 in size 
(~50mm height). Implant halves could be bonded with further cell-laden PLGA/PEG 
paste before sintering (Fig. 7D). Again PF127 gel could be removed by cold washing 
in PBS. This rapid prototyping of large personalized hard scaffolds, containing 
hMSCs and a differentiation initiator is the first demonstration of such an approach.   
 
3.10 Successful osteogenic hMSC differentiation in bioprinted scaffolds by 
GET-RUNX2 release 
To evaluate the differentiation response of hMSCs co-printed in 3D printed 
PLGA/PEG scaffolds, fabricated cell-laden scaffolds incorporating MPs. Both 
sintering and mechanical properties were similar when MPs were added to the 
formulation, aligning with previous studies using MP sintering [15, 32]. We next 
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carried out differentiation assays with hMSCs by using scaffolds containing GET-
RUNX2 MPs (60µg/ml GET-RUNX2/ml mixture). Cell-laden scaffolds were cultured 
in OP media, compared to those with blank MPs in OP or OI media, and monitored 
for 21 days. Differentiation was assessed by OCN staining at week 2, and von Kossa 
staining for mineralization at week 3 (Fig. S9; black staining is mineralized nodules; 
white particles the PLGA component). Results were comparable to those achieved 
without 3D printing (Fig. 4), demonstrating no loss of osteogenic commitment when 
cells were incorporated and 3D-printed within scaffolds, in comparison with seeding 
the cells on the scaffolds after sintering. Bone nodules (black staining, Fig. S9B) 
were observed with GET-RUNX2 which were comparable with that achieved without 
printing, or when cultured in OI media. This confirms that GET-RUNX2 MP system 
could be modified for bioprinting and could directly stimulate osteogenic 
differentiation of hMSCs fabricated within scaffolds. 
 
3.11 Regeneration of high density bone by GET-RUNX2 MPs in PLGA/PEG 
scaffolds in vivo 
A femoral drill-hole defect mouse model was used to assess the ability of the 
PLGA/PEG scaffolds containing GET-RUNX2 MPs to induce bone formation over a 
6 week period (Fig. 8, Fig. S10). Human STRO-1+ MSCs were added to scaffold and 
subsequently used to fill a 1 mm diameter drill-hole defect in the distal femur of 
athymic mice. In vivo CT scans of the defect region were taken at the time of surgery 
and additionally at 2, 4, and 6 weeks post-surgery in the same animal. The diameter 
of the analysed defect is 1mm, centred on the drill hole. The depth of the defect is 
the thickness of the cortical bone (approx. 250µm). The images captured were semi-
transparent and represent the bone density for the entire 3D reconstruction. This is a 
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better representation of the bone formation rather than an offset thin disc showing 
the thickness of the defect. The PLGA/PEG scaffold was not visible as it does not 
absorb any x-ray energy at the levels used for these scans. Although there was no 
apparent increase in the total bone volume formed within the defect site (Fig. S10), 
there was an increase in the volume of high density bone formed in GET-RUNX2 
scaffolds at 4 weeks, and a significant increase by 6 week post-surgery (Fig. 8B).  
The high density definition of bone generated here by GET-RUNX scaffolds is based 
on the intensity of signal measured by µCT as we have previously published [34] 
(lowest density bone set at 0.25 g/cm3).  
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4. Discussion 
GET-RUNX2 releasing PLGA MPs were prepared using S/O/W with high 
encapsulation efficiency as previously published [15]. We accelerated the protein 
release by incorporating PBS during the formulation. PBS works as a porogen, 
increasing MP porosity by generating channels within and on the MP surface [15, 
32]. Above 90% of the encapsulated P21-RUNX-8R was released in the first 7 day 
period (Fig. 1E). This release profile was developed to match the previous findings of 
dose requirements of GET-RUNX2-triggered osteogenic differentiation of hMSCs 
(i.e. two doses of 30µg/ml in the first week of the study) [9]. 
The challenging issues in controlled release system are encapsulating and releasing 
molecules that remain biologically active [48, 49]. We have previously shown that 
GET peptide activity is compromised in the presence of carboxylic acid group 
produced upon PLGA degradation. The use of L-Histidine was shown to maintain the 
activity of GET peptides upon release [15]. Consequently, L-Histidine was added to 
the formulation with the encapsulated P21-RUNX2-8R. In order to validate the 
biological functionality for P21-RUNX2-8R post-release, the transduction and 
subsequent transcriptional activity of the released protein was tested. The results 
showed that the released P21-RUNX2-8R has activity comparable to the 
experimental controls, confirming our previous findings and validating our delivery 
system for targeted delivery of such therapeutic molecules. 
Scaffolds were formed by mixing thermo-sensitive PLGA/PEG particles with blank or 
GET-RUNX2 loaded MPs. PBS was used to create a paste-like material, this was 
packed in PTFE moulds and incubated for 2 hours at 37ºC for sintering. This 
osteoconductive technology was previously described [27, 31] and been 
demonstrated as 3D printable [28]. However the biomaterial had not been used to 
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program osteogenic differentiation of hMSCs, or employed with GET technology 
incorporated. The use of this biodegradable polymer along with GET peptides 
controlled release delivery system would allow new in-vivo applications, mainly in 
bone regeneration. The ability to paste the scaffold at a defect site can offer 
improved clinical translation when compared to metallic implants [1]. Moreover, this 
material can be formulated with simple addition of PF127 and Tri-acetin to be 3D 
printable as demonstrated here; which gives the ability to fill complex and difficult to 
reach geometric defects or as a pre-fabricated implant [2]. 
PLGA/PEG scaffolds have potential to be used in vivo. Firstly the ability of hMSCs to 
attach, proliferate and differentiate on scaffolds in vitro was assessed. The results 
showed effective attachment and proliferation of hMSCs on the scaffolds over a 9-
day period, confirming cytocompatibility. Next, to prove these scaffolds could host 
osteogenic differentiation of hMSCs using GET-RUNX2 loaded MPs, we conducted 
several cell differentiation studies comparing pre-sintered (Fig.4) and 3D printed 
systems (Fig. 7). Differentiation markers showed comparable behaviour between 
scaffolds containing P21-RUNX2-8R loaded MPs and the scaffolds cultured in osteo-
inductive (OI) media. Differentiation was comparable between pre-sintered and 3D 
printed scaffolds (Fig. 4 and Fig.7). Encapsulation of genetically targeted biologics 
such as TFs in scaffolds should prevent off-target pleiotropic side-effects such as 
seen with high dose steroid or growth factor stimulation, should reduce the loss by 
diffusion of such regulatory molecules and will enable safe and effective tissue 
engineering strategies to be developed [3, 4]. The results show that GET-RUNX2 
can induce it’s own endogenous RUNX2 expression (Fig. 4 and Fig.7) compared to 
the samples containing no RUNX2. These findings, here in 3D scaffold structures, 
are comparable to our previous 2D differentiation findings using GET-RUNX2 to 
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program hMSCs [9]. The use of GET-RUNX2 loaded MPs will help in targeted stem 
cells reprograming, directly delivering the stimulus needed to induce the expression 
of osteogenic target genes. This strategy of delivering specific factors for promoting 
bone formation also helps in preventing undesirable, undirected differentiation which 
sometimes can see adipose or chondrogenic lineage induction and not bone from 
hMSCs, minimizing off-target or systemic side-effects. Our work culminated in 
demonstrating high-density bone regeneration in a mouse model which shows that 
the full system can have in vivo benefit in a formulation compatible with cells and 
additive manufacturing. Future work will now be to apply the system to larger pre-
clinical animal studies using more complex scaffold implants to confirm the 
mechanical and biological efficacy at human-sized scales. 
 
5. Conclusion 
A robust method of fabricating GET-RUNX2-loaded MPs using S/O/W emulsion 
technique was utilized providing a controlled release system. MPs were mixed with 
temperature sensitive materials that can solidify at body temperature providing a 
‘cancellous bone-like’, mechanically strong scaffold that can fill a bone defect inside 
the body or generate personalized implants. hMSCs seeded on or within these 
scaffolds can be induced towards osteogenesis in response to the TF RUNX2 
released from the co-formulated MPs. This delivery technology has potential to be 
valuable in the controlled delivery of various potent therapeutic molecules, including 
recombinant proteins coupled with GET peptides. We believe that our improved 
methods to generate hard osteoconductive, 3D bioprinted porous scaffolds that 
promote hMSC growth and osteogenesis in one combined formulation, has the 
potential to become a patient-applicable translational technology. Such integrated 
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systems will be vital for new innovative classes of personalized cell-based therapies 
and regenerative medicine for treating trauma and disease to be exploited. 
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'Highlights' file (including 3 to 5 bullet points; maximum 85 characters each) 
 
 Efficient osteogenic programming of hMSCs by cell-transducing GET-RUNX2. 
 Osteogenesis by controlled release of GET-RUNX2 from PLGA MPs. 
 Mechanically strong biodegradable PLGA/PEG scaffolds containing MPs & hMSCs.  
 3D bioprinting of cell- and MP-laden scaffolds for personalized implants. 
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